Form 4: Cargo Therapeutics Director, Kapil Dhingra, Acquires Stock Options

Kapil Dhingra, a director at Cargo Therapeutics, acquired stock options for 11,871 shares on June 4, 2024.

Summary

• Kapil Dhingra, a director of CARGO Therapeutics, Inc., filed a Form 4 on June 6, 2024, reporting a transaction.
• On June 4, 2024, Dhingra acquired stock options for 11,871 shares of CARGO Therapeutics common stock at an exercise price of $19.17.
• These options vest on the earlier of June 4, 2025, or the next Annual Meeting following June 4, 2024, contingent upon continued service to the Issuer.
• Following the transaction, Dhingra directly owns options for 11,871 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The vesting conditions suggest a positive outlook for continued service.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting of the stock options is contingent upon the Reporting Person's continued service to the Issuer, incentivizing continued involvement.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This allows investors to monitor the actions of those with the most knowledge of the company's prospects.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's success.

Key Dates